Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma - PDAC-GS/GA-rP2, CSGO-HBP-015

Clinical study group of Osaka university, Hepato-Biliary- Pancreatic group0 个研究点目标入组 100 人开始时间: 2016年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Unresectable pancreatic cancer 2) Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings. 3) Watery diarrhea 4) Severe infection 5) Severe complication (heart failure, renal failure, hepatic insufficiency,hemorrhagic peptic ulcer, intestines paralysis,ileus or uncontrolled diabetes etc) 6) Massive pleural or abdominal effusion. 7) Metastasis to central nervous system. 8) Active synchronous or metachronous malignancy other than carcinoma in situ. 9) Regular use of frucitocin, fenitoin or warfarin 10) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy 11) Severe mental illness 12) Severe allergy for drugs 13) Patients who are judged inappropriate for the entry into the study by the investigator.

发起方

Clinical study group of Osaka university, Hepato-Biliary- Pancreatic group